​

Definium Therapeutics (DFTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

DFTX Stock Forecast

Definium Therapeutics (DFTX) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $61.27, with a high of $75.00 and a low of $25.00. This represents a 34.96% increase from the last price of $45.40.

DFTX Stock Rating

Definium Therapeutics stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 12 Strong Sell Sell Hold Buy Strong Buy

DFTX Price Target Upside V Benchmarks

TypeNameUpside
StockDefinium Therapeutics34.96%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts81424
Avg Price Target$67.13$62.64$51.58
Last Closing Price$45.40$45.40$45.40
Upside/Downside47.86%37.97%13.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 26412---16
Jul, 26411---15
Jun, 26412---16
May, 26412---16
Apr, 26311---14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 14, 2026Maxim Group$55.00$42.8828.26%21.15%
Aug 13, 2026Sumant KulkarniCanaccord Genuity$64.00$42.7949.57%40.97%
Aug 13, 2026Robert W. Baird$75.00$42.7975.27%65.20%
Aug 12, 2026RBC Capital$66.00$42.7954.24%45.37%
Aug 12, 2026Needham$66.00$42.7954.24%45.37%
Aug 12, 2026Oppenheimer$70.00$43.0562.60%54.19%
Jul 27, 2026Benjamin BurnettWells Fargo$68.00$43.1757.52%49.78%
Jul 24, 2026Piper Sandler$73.00$42.9370.04%60.79%
Jul 08, 2026Stifel Nicolaus$60.00$44.4834.89%32.16%
Jun 30, 2026Canaccord Genuity$58.00$46.5524.60%27.75%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 12, 2026RBC CapitalOutperformOutperformhold
Aug 12, 2026NeedhamBuyBuyhold
Aug 12, 2026OppenheimerOutperformOutperformhold
Jul 27, 2026Wells FargoOverweightinitialise
Jul 24, 2026Piper SandlerOverweightOverweighthold
Jun 25, 2026UBSPositivePositivehold
Jun 23, 2026NeedhamBuyBuyhold
Jun 22, 2026CitigroupBuyBuyhold
Jun 22, 2026OppenheimerOutperformOutperformhold
Jun 22, 2026RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.54$-2.06----
Avg Forecast$-1.43$-2.01$-1.81$-1.75$-0.58$0.95
High Forecast$-1.43$-1.81$-1.05$-0.50$3.60$0.95
Low Forecast$-1.43$-2.14$-2.20$-2.37$-2.31$0.95
Surprise %7.69%2.49%----

Revenue Forecast

$0 $110M $220M $330M $440M $550M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported------
Avg Forecast---$39.36M$213.34M$515.74M
High Forecast---$39.36M$221.96M$515.74M
Low Forecast---$39.36M$204.71M$515.74M
Surprise %------

Net Income Forecast

$-2B $-1B $0 $1B $2B $3B Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-108.68M$-183.79M----
Avg Forecast$-1.01B$-1.39B$-1.15B$-1.01B$-43.50M$671.73M
High Forecast$-1.01B$-1.27B$-738.99M$-354.75M$2.54B$671.73M
Low Forecast$-1.01B$-1.51B$-1.55B$-1.67B$-1.63B$671.73M
Surprise %-89.23%-86.79%----

DFTX Forecast FAQ

Is Definium Therapeutics stock a buy?

Definium Therapeutics stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Definium Therapeutics is a favorable investment for most analysts.

What is Definium Therapeutics's price target?

Definium Therapeutics's price target, set by 12 Wall Street analysts, averages $61.27 over the next 12 months. The price target range spans from $25 at the low end to $75 at the high end, suggesting a potential 34.96% change from the previous closing price of $45.4.

How does Definium Therapeutics stock forecast compare to its benchmarks?

Definium Therapeutics's stock forecast shows a 34.96% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Definium Therapeutics over the past three months?

  • August 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 26.67% Strong Buy, 73.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Definium Therapeutics’s EPS forecast?

Definium Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.81, marking a -12.14% decrease from the reported $-2.06 in 2025. Estimates for the following years are $-1.75 in 2027, $-0.58 in 2028, and $0.95 in 2029.

What is Definium Therapeutics’s revenue forecast?

Definium Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $39.36M, followed by $213.34M for 2028, and $515.74M for 2029.

What is Definium Therapeutics’s net income forecast?

Definium Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-1.145B, representing an 523.22% increase from the reported $-184M in 2025. Projections indicate $-1.012B in 2027, $-43.5M in 2028, and $671.73M in 2029.